Comparison of ranibizumab in monotherapy versus association with | 56141
Journal of Clinical and Experimental Ophthalmology

Journal of Clinical and Experimental Ophthalmology
Open Access

ISSN: 2155-9570

Comparison of ranibizumab in monotherapy versus association with intravitreal dexamethasone in diabetic macular oedema

16th International Conference on Clinical and Experimental Ophthalmology

September 18-20, 2017 | Zurich, Switzerland

Zuzana Schlegel

Laser Vision Schlegel, Reunion Island

Scientific Tracks Abstracts: J Clin Exp Ophthalmol

Abstract :

Introduction: To evaluate the efficacy of single intravitreal injections of ranibizumab compared with association with dexamethasone implant in diabetic macular oedema in anatomical, functional, safety and observance terms. Material and Methods: 60 patients suffering from diabetes mellitus were randomized into two groups. 30 patients received ranibizumab (R) injection as monotherapy, in three loading doses during first three months and thereafter depending on development of their visual acuity. Other 30 patients received, the simultaneous intravitreal injection of dexamethasone sustained-release implant (Ozurdex) with the first injection of ranibizumab (RD). The variation of BCVA and other criteria was observed monthly up to the twelve months. Results: The improvement of BCVA was superior in the combination treatment group RD than in monotherapy group R. The RD group patients gained 13 letters and the R group 10 letters, p = 0,031. The reduction of central retinal thickness was equally more important in the RD group, -177 ?µm, than in the R group, -127 ?µm, p < 0,001, compared to the income values, the chorioretinal atrophy was not remarked. Discussion: Up to this date there exists very few papers about the simultaneous administration of the two products, other than LuceDex study in the ARMD, whose results was also in favour of association of the intravitreal ranibizumab with dexamethasone implant. Conclusion: One year outcomes reveal the functional and anatomical superiority, safety and diminution of total number of interventions conducting in better observance, using combined RD intravitreal treatment versus single R monotherapy in diabetic macular edema.

Biography :

Zuzana Schlegel completed her specialisation in ophthalmology in 2002, in the Department of Ophthalmology of F.D. Roosevelt University Hospital, headed by Prof. Milan IZAK, PhD, FEBO, and from 2005 she continued and upgraded her training and surgical skills in France, particularly in A de Rothschild Foundation and National Centre of Ophthalmology Quinze-Vingts, headed by Prof. Thanh HOANG-XUAN and Prof. Christophe Baudouin respectively. She is working in Reunion Island as a Consultant and Surgeon in her own private practice. She had published and communicated at least 23 scientific papers and indexed international Ophthalmological journals, reviews and conferences.